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Abstract
Group B streptococcus (GBS) strains with the highest ability to bind to human fibrinogen belong to the highly invasive
clonal complex (CC) 17. To investigate the fibrinogen-binding mechanisms of CC17 strains, we determined the prevalence
of fibrinogen-binding genes (fbsA and fbsB), and fbs regulator genes (rogB encoding an fbsA activator, rovS encoding an fbsA
repressor and rgf encoding a two-component system [TCS] whose role on fbs genes was not determined yet) in a collection
of 134 strains representing the major CCs of the species. We showed that specific gene combinations were related to
particular CCs; only CC17 strains contained the fbsA, fbsB, and rgf genes combination. Non polar rgfAC deletion mutants of
three CC17 serotype III strains were constructed. They showed a 3.2- to 5.1-fold increase of fbsA transcripts, a 4.8- to 6.7-fold
decrease of fbsB transcripts, and a 52% to 68% decreased fibrinogen-binding ability, demonstrating that the RgfA/RgfC TCS
inhibits the fbsA gene and activates the fbsB gene. The relative contribution of the two fbs genes in fibrinogen-binding
ability was determined by constructing isogenic fbsA, fbsB, deletion mutants of the three CC17 strains. The ability to bind to
fibrinogen was reduced by 49% to 57% in DfbsA mutants, and by 78% to 80% in DfbsB mutants, suggesting that FbsB
protein plays a greater role in the fibrinogen-binding ability of CC17 strains. Moreover, the relative transcription level of fbsB
gene was 9.2- to 12.7-fold higher than that of fbsA gene for the three wild type strains. Fibrinogen-binding ability could be
restored by plasmid-mediated expression of rgfAC, fbsA, and fbsB genes in the corresponding deletion mutants. Thus, our
results demonstrate that a specific combination of fbs genes and fbs regulator genes account for the high fibrinogen-
binding ability of CC17 strains that may participate to their enhanced invasiveness for neonates as compared to strains of
other CCs.
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Introduction
Streptococcus agalactiae (group B streptococcus [GBS]) frequently
asymptomatically colonizes the intestinal and/or urogenital tract
of humans. It is the leading cause of invasive infections in neonates
and has emerged as an increasingly cause of invasive diseases in
immunocompromised and elderly adults [1,2]. Several studies
have emphasized the clonal structure of GBS species and
demonstrated that GBS diseases are mostly caused by a limited
set of clonal lineages [3–8]. Indeed, strains belonging to clonal
complex (CC) 17 appear to be strongly able to invade the central
nervous system (CNS) of neonates [9–13]. The remarkable homo-
geneity within this highly virulent lineage is likely of importance
for disease pathogenesis, though few studies have been conducted
to identify specific differences in virulence characteristics between
lineages.
Various molecules either secreted or located at the bacterial
surface account for the pathogenicity of GBS strains [14–17].
Among these molecules, FbsA and FbsB are proteins with no
structural homology which both bind to human fibrinogen,
mediate the bacterial adhesion to or invasion of epithelial and
endothelial cells, and contribute to the bacterial escape from the
immune system [18–22]. Deletion of the fbsB gene that has been
described for a unique strain belonging to CC23 phylogenetic
lineage, did not attenuate its fibrinogen-binding ability; conversely,
deletion of the fbsA gene in this strain resulted in a loss of
fibrinogen-binding activity, thus suggesting that FbsA protein was
the major fibrinogen-binding protein in GBS [18,20,21]. Howev-
er, while studying a collection of 111 human strains, we showed
that the presence of the sole fbsA gene was not sufficient to result in
strong binding ability to fibrinogen [17]. Indeed, the population of
strains with the significantly highest ability to bind to fibrinogen
had both the fbsB and fbsA genes and belonged to CC17
phylogenetic lineage [17]. Thus, the role of fbs genes and in
particular the fbsB gene in the fibrinogen-binding ability of CC17
strains remains unclear and requires further investigation.
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gene transcription in a CC23 GBS strain: RogB, a member of the
RALP (RofA-like proteins) family, exerts a positive effect [23], and
RovS, relative to the Rgg family of Gram-positive transcriptional
regulators, exerts a negative effect [24]. In addition, Spellerberg
et al. described a two-component system (TCS), the regulator of
fibrinogen-binding rgfBDAC operon that principally encodes the
response regulator RgfA and the histidine kinase RgfC [25].
Disruption of the rgfC gene altered the bacterial binding to
fibrinogen. The role of rgf locus on fbs genes transcription was not
studied yet, and it can be speculated that fbsA and/or fbsB genes
are under the transcriptional control of the RgfA/RgfC TCS.
To investigate the mechanisms allowing the high fibrinogen-
binding ability of CC17 strains (i) we determined the fbs genes and
fbs regulator genes profile of 38 CC17 strains as compared to 96
GBS strains of the other four major phylogenetic lineages
constituting this species, and found that specific gene combinations
were related to particular CCs; (ii) we constructed non polar rgfAC
deletion mutants of three CC17 strains in order to determine the
role of rgf locus on fbs genes transcription; (iii) we quantified the
transcription levels of fbsA and fbsB genes of these three strains, and
constructed their fbsA and fbsB deletion mutants in order to
determine the relative contribution of fbs genes in the fibrinogen-
binding ability of CC17 strains.
Results
Prevalence of the fbs genes and of the fbs regulator
genes in strains of CC17 and of the major other GBS
clonal complexes
PCRwasperformedtocharacterizethe presenceoffbsgenes(fbsA
and fbsB) and their regulator genes (rogB, rovS and rgf) in a collection
of 134 isolates representing the major clonal complexes of GBS
species: CC1 (29 strains), CC10 (26 strains), CC17 (38 strains),
CC19 (21 strains), and CC23 (20 strains) (Table 1). The fbsA gene
was found in all CC17 and CC23 strains, in most strains of CC10
(92.3%) and CC1 (82.8%), and in only 23.8% of CC19 strains. The
fbsB gene was found in all CC17 strains, in 75.0% of CC23 strains,
and in only one CC19 strain (4.8%), whereas the CC1 and CC10
strains did not have an fbsB gene. The rovS gene was found in all
strains of all the CCs. The rogB gene was found in all CC1, CC10,
CC19 and CC23 strains and in only 21.0% of CC17 strains. The rgf
locus was found in all CC17 and CC10 strains, in most CC1 strains
(93.1%), and rarely in CC19 (14.3%) and CC23 (25.0%) strains.
Thus, CC1andCC10 strains sharedthesame profile containingthe
various fbs regulator genes and the fbsA gene, but not the fbsB gene.
Most of CC19 strains lacked the fbsA and fbsB genes. The
simultaneous presence of fbsA and fbsB genes was restricted to
CC17 (100%) and CC23 (75%) strains. However, the regulator
genes profile of these two groups of strains differed, since rgf locus
and rogB gene were associated with CC17 and CC23, respectively.
These data show that different fbs genes and fbs regulator genes
profiles are related to the GBS phylogenetic lineages, and that
CC17 strains have a unique configuration characterized by the fbsA,
fbsB, rovS,and rgf genes combination and the absence of rogB gene.
Expression of fbsA and fbsB genes in three non polar
deletion DrgfAC mutant strains
As the fbsA, fbsB and rgf genes combination was strictly restricted
to the CC17 strains and that the role of the RgfA/RgfC TCS on
the fbsB and fbsA genes expression was not explored yet, we
constructed non polar deletion DrgfAC mutants of serotype III
strains belonging to CC17 phylogenetic lineage. Since phenotypes
can be strain specific despite genetic similarity, we constructed
mutants of three epidemiologically unrelated isolates, L1, L2 and
L50 strains that were isolated from the cerebrospinal fluid (CSF) of
neonates suffering from meningitis. In these mutants, the last 374
bp of rgfA gene encoding the DNA-binding domains, as well as the
first 1,055 bp of the 1,278-bp rgfC gene were deleted (Fig. 1). By
quantifying the transcription level of downstream gene, we
checked that these mutations were non polar. Real time RT-
PCR was then used to quantify the transcription levels of fbsA and
fbsB genes in the three DrgfAC mutant strains and in the parental
strains (Fig. 2A). As compared to L1, L2, and L50 wild type
strains, the transcription levels of the fbsB gene were respectively
6.6760.47-, 5.2860.54-, and 4.8260.14-fold decreased in DrgfAC
mutants. By contrast, the transcription levels of the fbsA gene were
respectively 5.0760.30-, 3.4560.05-, and 3.2460.32-fold in-
creased in DrgfAC mutant strains as compared to the wild type
strains. These results indicate that RgfA/RgfC exerts a negative
effect on the transcription of the fbsA gene, and that it activates the
transcription of the fbsB gene in CC17 isolates.
To investigate whether RgfA/RgfC regulated fbs genes through
the rovS gene that encodes an fbsA inhibitor, we quantified the rovS
gene transcription levels in L1 DrgfAC mutant as compared to the
parental strain, and found no significant difference (1.2960.11-
fold that of the wild type strain).
Binding of the three DrgfAC mutant strains to
immobilized human fibrinogen
To further characterize the three DrgfAC mutant strains, we
compared their fibrinogen-binding ability with that of the wild
Table 1. Prevalence of the fbs genes and of their regulator
genes in a collection of 134 isolates belonging to the GBS
major clonal complexes.
Clonal complexes (CC)
CC17 CC19 CC23 CC1 CC10
N6 (%) N6 (%) N6 (%) N6 (%) N6 (%)
n=38 n=21 n=20 n=29 n=26
fbsA 38 (100.0) 5 (23.8) 20 (100.0) 24 (82.8) 24 (92.3)
fbsB 38 (100.0) 1(4.8) 15 (75.0) 0 (0.0) 0 (0.0)
rovS 38 (100.0) 21 (100.0) 20 (100.0) 29 (100.0) 26 (100.0)
rogB 8 (21.0) 21 (100.0) 20 (100.0) 29 (100.0) 26 (100.0)
rgf 38 (100.0) 3 (14.3) 5 (25.0) 27 (93.1) 26 (100.0)
doi:10.1371/journal.pone.0014658.t001
Figure 1. Schematic representation of the rgf locus. Open
reading frames, direction of transcription and approximate gene sizes
are indicated [25]. The segment that was deleted in DrgfAC mutant is
represented as a heavy line below the genes.
doi:10.1371/journal.pone.0014658.g001
fbsB and rgf in CC17 GBS
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bound to fibrinogen was respectively 22.5% 62.4%, 25.3%
61.4%, and 23.2% 63.4% for the three wild type strains, and
7.3% 60.8%, 10.2% 61.6%, and 11.2% 61.1% for the isogenic
DrgfAC mutants. Thus, as depicted in Fig. 2B, the three DrgfAC
mutants showed respectively a 68%, 60%, and 52% decreased
fibrinogen-binding ability as compared to L1, L2, and L50 wild
type strains (P,0.001). Furthermore, plasmid-mediated expression
Figure 2. Properties of DrgfAC mutant strains. (A) Fold change in transcription levels of fbsA (filled boxes) and fbsB (open boxes) genes in the
isogenic DrgfAC mutants as compared to the wild type L1, L2, and L50 strains (WT). The amount of transcripts of each gene was normalized to the
amount of gyrA transcripts and expressed relative to the level of transcription in corresponding WT strain. Each experiment was performed at least
three times. Boxes are means and bars are standard deviation of the means. (B) Binding ability to immobilized human fibrinogen of the isogenic
DrgfAC mutants (open boxes) and the WT strains (filled boxes). Flat bottomed 96-well polystyrene plates were coated with 21 nM human fibrinogen
and 5610
6 to 5610
8 CFU per ml were added for 90 min at 37uC. Binding ability was calculated from the ratio between the number of bound bacteria
and the number of bacteria present in the inoculum. The level of fibrinogen binding of WT strains is arbitrarily reported as 100 and the fibrinogen-
binding levels of the isogenic mutants are relative values. Each experiment was performed at least three times. Boxes are means and bars are
standard deviation of the means. * indicates that the binding values of the mutant strains were significantly lower than the values of the
corresponding WT strains, at a P value of ,0.001.
doi:10.1371/journal.pone.0014658.g002
fbsB and rgf in CC17 GBS
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ability to the wild-type level. Indeed, as shown in Fig. 3, the
fibrinogen-binding ability of the complemented strain L1DrgfAC/
pP1-rgfAC (26.5% 62.6%) was significantly higher (P,0.001) than
that of L1DrgfAC mutant (7.3% 60.8%) and was similar to that of
the wild type L1 strain (22.5% 62.4%).
Binding of DfbsA, DfbsB, and DfbsADfbsB mutant strains
to immobilized human fibrinogen
In order to investigate the relative contribution of FbsA and
FbsB proteins in the interaction of GBS CC17 strains with human
fibrinogen, fbsA and fbsB genes were deleted in the genome of L1,
L2 and L50 strains, and both genes were deleted in the genome of
L1 strain. The growth curves of the mutants and of the wild type
parental strains in TH broth did not differ significantly. The wild
type strains and their isogenic mutants (DfbsA, DfbsB, and
DfbsADfbsB) were subsequently tested for their fibrinogen-binding
ability. For L1 strain, the percentage of bacteria that bound to
fibrinogen was 22.5% 62.4% for wild type strain, 10.1% 61.7%
for DfbsA, 4.5% 61.6% for DfbsB, and 2.2% 60.7% for
DfbsADfbsB. Thus, as shown in Fig. 4, deletion of fbsA gene
reduced the fibrinogen-binding ability of L1 wild type strain by
55% (P,0.001), whereas deletion of fbsB gene resulted in a 80%
decrease (P,0.001), and deletion of both fbsA and fbsB genes
resulted in a 90% decrease of this ability (P,0.001). Similar results
were obtained with DfbsA and DfbsB mutants of L2 and L50 strains
(Fig. 4). Moreover, the fibrinogen-binding abilities of DfbsB and of
DfbsADfbsB mutant strains were significantly lower than those of
DfbsA mutant strains (P,0.001). In addition, plasmid-mediated
expression of fbsA and of fbsB in L1DfbsA and in L1DfbsB mutants,
respectively, restored their fibrinogen-binding ability to the wild-
type level. Indeed, as shown in Fig. 3, the fibrinogen-binding
ability of the complemented strains L1DfbsA/pP1-fbsA (20.9%
63.8%) and L1DfbsB/pP1-fbsB (24.1% 64.3%) were significantly
higher (P,0.001) than those of L1DfbsA (10.1% 61.7%) and
L1DfbsB (4.5% 61.6%) mutants and were similar to that of the
wild type L1 strain (22.5% 62.4%). Taken together, these data
suggest a greater role of the fibrinogen-binding protein FbsB as
compared to FbsA in the binding ability to human fibrinogen of
CC17 GBS strains.
Relative transcription level of fbsA and fbsB genes
In order to determine if the greater role of FbsB as compared to
FbsA in the binding ability to fibrinogen of CC17 strains was
related to a higher transcription of fbsB, we quantified fbsA and
fbsB gene transcripts by real-time PCR in the three wild type
strains L1, L2 and L50. As shown in Fig. 5, the relative
transcription level of fbsB gene was respectively 12.2462.38-,
12.6763.30- and 9.1762.19-fold higher than that of fbsA gene for
the three strains.
Quantification of fbsA and fbsB gene transcripts in
mutant strains
By real-time PCR, we quantified the transcript levels of fbsA and
fbsB genes in DfbsA, DfbsB, and DfbsADfbsB mutants and in the
parental strain L1. As expected, no fbsA transcripts were detected
in DfbsA and in DfbsADfbsB mutants; likewise, no fbsB transcripts
were detected in DfbsB and DfbsADfbsB mutants. Deletion of fbsA
gene had no significant effect on the fbsB gene transcription, since
in DfbsA mutant, the transcription level of fbsB was 1.460.2-fold
that of the wild type strain. Similarly, deletion of fbsB gene had no
significant effect on the fbsA gene transcription since the
transcription level of fbsA in DfbsB mutant was 0.9660.03-fold
that of the wild type strain. These data demonstrate that the fbsA
and fbsB genes expression are independent of each other.
Discussion
Overrepresentation of CC17 clone among invasive neonatal
strains is now well recognized worldwide [9-13], and highlights the
Figure 3. Binding ability to immobilized human fibrinogen of the wild type (WT) L1 strain, and of isogenic mutant and
complemented strains for rgfAC, fbsA, and fbsB genes. Flat bottomed 96-well polystyrene plates were coated with 21 nM human fibrinogen
and 5610
6 to 5610
8 CFU per ml were added for 90 min at 37uC. Binding ability was calculated from the ratio between the number of bound bacteria
and the number of bacteria present in the inoculum. Each experiment was performed at least three times. Boxes are means and bars are standard
deviation of the means. The binding values of the mutant strains were significantly lower, at a P value of ,0.001, than the values of the L1WT strain
and of the corresponding complemented strains carrying rgfAC, fbsA, and fbsB genes on the pP1 plasmid.
doi:10.1371/journal.pone.0014658.g003
fbsB and rgf in CC17 GBS
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pathogenesis and may possess specific virulence traits that enhance
CNS invasiveness in this population [14,26]. We here studied the
molecular events involved in the fibrinogen-binding ability of
CC17 strains that were previously shown to bind significantly
more strongly to human fibrinogen than strains of other lineages
that constitute the species [17]. We first looked for the fbs genes
and the fbs regulator genes in a collection of 134 GBS isolates
belonging to the major GBS phylogenetic lineages. No gene was
specific of either CC17 or other CCs strains, but specific gene
combinations were related to particular CCs, indicating that
fibrinogen binding is a multigenic process that results from various
gene combinations. Only CC17 strains contained the fbsA, fbsB,
and rgf genes combination. The rogB gene was rarely found in
CC17 strains but present in all strains of other CCs. Accordingly,
the rogB gene is missing in the sequenced genome of CC17 strain
COH1 [27], and the absence of this gene was also reported in a
collection of 20 CC17 strains [14]. Thus, each CC was
characterized by a particular profile of fbs genes and fbs gene
regulators that may account for differences in their fibrinogen-
binding abilities.
As only CC17 strains contained the fbsA, fbsB, and rgf genes
combination, we constructed non polar DrgfAC mutants of three
serotype III CC17 strains that showed a 52% to 68% decreased
binding ability to fibrinogen, a 4.8- to 6.7-fold decreased transcript
level of fbsB gene, and at the same time a 3.2- to 5.1-fold increased
transcript level of fbsA gene. These data demonstrate that RgfA/
RgfC is implicated in fbsB gene activation and in fbsA gene
inhibition. Spellerberg et al. have described that the response
regulator RgfA and the histidine kinase RgfC display respectively
55% and 45% similarities with AgrA and AgrC of Staphylococcus
aureus [25]. The accessory gene regulator (agr) locus consists of the
four cotranscribed agrBDCA genes that regulate the expression of S.
aureus virulence factors. In general, secreted proteins, including
several of the known S. aureus toxins, are up-regulated by agr
whereas surface proteins such as protein A and extracellular
matrix adhesins are down-regulated [28–32]. Thus, our results
showing the increased transcription of the fbsA gene encoding a
surface protein, as well as the decreased transcription of the fbsB
gene encoding a secreted protein in DrgfAC mutant strain, are in
agreement with the control of cell surface and secreted molecules
Figure 4. Binding ability to immobilized human fibrinogen of the wild type (WT) S. agalactiae strains and isogenic DfbsA, DfbsB,
DfbsADfbsB deletion mutants. Flat bottomed 96-well polystyrene plates were coated with 21 nM human fibrinogen and 5610
6 to 5610
8 CFU per
ml were added for 90 min at 37uC. Binding ability was calculated from the ratio between the number of bound bacteria and the number of bacteria
present in the inoculum. The fibrinogen-binding level of WT L1, L2, and L50 strains is arbitrarily reported as 100 and the fibrinogen-binding levels of
the various isogenic mutants are relative values. Each experiment was performed at least three times. Boxes are means and bars are standard
deviation of the means. * indicates that the binding values of the mutant strains were significantly lower than the values of the corresponding WT
strains, at a P value of ,0.001. { indicates that the binding values of the DfbsB and DfbsADfbsB mutant strains were significantly lower than the values
of DfbsA mutant strains, at a P value of ,0.001.
doi:10.1371/journal.pone.0014658.g004
Figure 5. Transcription levels of fbsA and fbsB genes in three
wild type CC17 strains. The amount of transcripts of fbsA gene (filled
boxes) and fbsB gene (open boxes) in L1, L2, and L50 wild type strains
was normalized to the amount of gyrA transcripts. Each experiment was
performed at least three times. Boxes are means and bars are standard
deviation of the means.
doi:10.1371/journal.pone.0014658.g005
fbsB and rgf in CC17 GBS
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that rgf locus down regulated the surface-anchored C5a peptidase
scpB gene [25]. Response regulators may modify genes expression
by direct binding to the genes promoters or by action on other
regulators that, in turn regulate target genes expression [16,33–
36]. As RovS was shown to directly bind to the promoter of fbsA
and hence to negatively regulate its transcription [24], we
quantified rovS transcript levels in a DrgfAC mutant in order to
determine whether RgfA/RgfC regulated fbsA through rovS gene.
We found that the rovS transcription was not altered in this mutant.
Thus, it is likely that RgfA/RgfC- and RovS- mediated control of
fbsA are independent of each other. Finally, RgfA/RgfC appears
to be an important multigene regulator in the hyper virulent CC17
lineage, and is therefore worthy of further disease association
studies.
Phenotypic comparison of three CC17 wild type strains with
their mutants deleted for the fbsA and fbsB genes demonstrated that
FbsB protein was the major fibrinogen binding protein of these
strains. Indeed, inactivation of the fbsB gene substantially reduced
fibrinogen-binding ability (78 to 80%), while deletion of fbsA gene
reduced only partially (49 to 57%) this ability. Our findings
showing the implication of both FbsA and FbsB proteins in the
fibrinogen-binding ability of CC17 strains with a major role of
FbsB are in contrast with previous reports suggesting that FbsA
protein was the major fibrinogen-binding protein in the CC23
serotype III 6313 GBS strain [18,20,21]. The reasons for these
phenotype differences between isolates are not completely
understood but can be related to differences in fbs genes regulation
depending on the genetic background of the GBS strains.
Interestingly, CC17 strains and CC23 6313 strain that both
contain fbsA and fbsB genes, possess a distinct fbs regulator profile:
contrarily to CC17 strains, 6313 strain has no functional rgfBDAC
locus and moreover possesses rogB gene [23]. This configuration
that leads to an up-regulation of the fbsA gene, is thus in agreement
with the major role of FbsA in the fibrinogen-binding process of
CC23 strains. On the contrary, the higher implication of FbsB as
compared to FbsA in the fibrinogen-binding ability of CC17
strains may be explained by the fact that the fbsA gene expression
is inhibited by two mechanisms: on one hand by the RgfA/RgfC
inhibitor, and on the other hand by the absence of the RogB
activator. Indeed, in the three CC17 strains studied, the mean
transcription level of fbsB gene was significantly higher (11.461.9-
fold) than that of fbsA gene. Thus, depending on the genetic
background of the GBS strains, several fbs regulatory circuits may
be defined and may account for the differences in the relative
implication of fbs genes in GBS binding-ability to human
fibrinogen.
In conclusion, our results demonstrate that a specific combina-
tion of fbs genes and fbs regulator genes may account for the
CC17 strains enhanced ability to bind to human fibrinogen, a
host protein whose synthesis is dramatically increased during
inflammation or under exposure to stress such systemic infections
[37].
Materials and Methods
Bacterial strains and growth conditions
A total of 134 unrelated human strains representing the genetic
diversity of S. agalactiae species were included in the present study:
52 strains from the CSF of infected neonates, 16 strains from the
gastric fluid of colonized asymptomatic neonates, 26 strains from
vaginal swabs of colonized asymptomatic pregnant women, and 40
strains from infected nonpregnant adult patients. Neonatal
specimens were obtained from infected neonates suffering of
meningitis and from non infected neonates with risk factor, and
vaginal specimens were obtained from asymptomatic pregnant
women during the process of routine clinical diagnostic proce-
dures, as part of the usual prenatal and postnatal screening. All
these strains were isolated between 1986 and 1990 from 25 general
hospitals throughout France [7]. According to the information we
obtained from the Institutional Review Board (more than 20 years
ago), this type of strains did not require an ethics approval and the
patient consent. Adult specimens were isolated from sites of
infection (skin, osteoarticular, and blood infections) of patients
admitted to hospitals in various regions of France from 2002 to
2008. The local ethical committee (CPP, Comite ´ de Protection des
Personnes, Tours-Centre) exempted the study of adult specimens
from review because they were of existing diagnostic specimens,
and waived the need for consent due to the fact that the samples
received were analyzed anonymously.
All strains had previously been serotyped on the basis of
capsular polysaccharides or by PCR [7,38]. Six serotypes were
identified i.e. serotypes Ia (19 strains), Ib (18 strains), II (17 strains),
III (51 strains), IV (2 strains), and V (23 strains), and four strains
were not typeable. All strains had previously been analyzed by
MLST according to Jones et al. [5]. Strains were grouped into
clonal complexes (CCs) that include isolates sharing five to seven
identical alleles.
GBS strains were stored at 280uC in Schaedler-vitamin K3
broth (bioMe ´rieux, Marcy l’Etoile, France) with 10% glycerol.
The bacteria were grown for 24 h on 5% horse blood Trypticase
soja (TS) agar plates (bioMe ´rieux) at 37uC.
EscherichiacoliDH5a and MC1061 were used for cloning purposes.
They were grown at 37uCi nL u r i aB r o t h .E. coli and GBS clones
carrying the pG
+host5 and pP1 plasmids were selected in the
presence of 300 mg/ml and 2 mg/ml erythromycin, respectively.
Construction of S. agalactiae mutants
The thermosensitive plasmid pG
+host5 [39] was used for the
construction of mutants of the CC17 serotype III L1 wild type GBS
strain deleted for fbsA gene,forfbsB gene, for both genes, and for rgfAC
genes by a method previously described by Schubert et al. [20]. For
the deletion of fbsA gene, two DNA fragments flanking the fbsA gene
were amplified by PCR using the primer set fbsA_del1 (59-
CCGCGGATCCGAATATGCTACCATCAC)/fbsA_del2 (59-C-
CCATCCACTAAACTTAAACA TTCCTGATTTCCAAGTTC) and
the primer set fbsA_del3 (59-TGTTTAAGTTTAGTGGATG GGGC-
TGCGGTTTGAGACGC)/fbsA_del4 (59-TGGCACAAGCTTT-
ACCTGCTGAGCGACTTG).ComplementaryDNAsequences in
the primers fbsA_del2 and fbsA_del3 are shown in italics, and the
BamHI and HindIII restrictions sites in primers fbsA _del1 and fbsA
_del4 are underlined. The fbsA-flanking PCR products were mixed in
equal amounts and subjected to a crossover PCR with the primers
fbsA _del1 and fbsA _del4, resulting in one PCR product that carried
the two fbsA-flanking regions. The crossover PCR product and the
plasmid pG
+host5 were digested with BamHIandHindIII, ligated and
transformed into E. coli DH5a. The resulting plasmid,
pG
+host5DfbsA, was electroporated into GBS L1 isolate [40], and
transformants were selected by growth on erythromycin (2 mg/ml)
TS agar at 28uC. Cells in which pG
+host5DfbsA h a di n t e g r a t e di n t o
the chromosome were selected by growth of the transformants at
$37uC with erythromycin selection. Four of such clones were serially
passaged for 6 days in Todd-Hewitt (TH) broth (Sigma, St Quentin
Fallavier, France) at 28uC without antibiotic pressure to facilitate the
excision of plasmid pG
+host5DfbsA,l e a v i n gt h ed e s i r e dfbsA deletion
in the chromosome. Dilutions of the serially passaged cultures were
plated onto TS agar and single colonies were tested for erythromycin
susceptibility to identify pG
+host5DfbsA excisants.
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strain and in L1DfbsA mutant strain as described above, using the
following primers: fbsB_del1 (59-CCGCGGATCCGTCATGT-
TACTAATCTTATGC), fbsB_del2 (59-CCCATCCACTAAACTTA
ACACAATCCAAAACGCAATAGG), fbsB_del3 (59-TGTTTA-
AGTTTAGTGGATGGGGATC AAGCTTTTGTAGCTAG), and
fbsB_del4 (59-GGGGGTACCCTTCATTAACAATATCTG AG).
The non polar deletion mutant strain DrgfAC was constructed by
deletion of the last 374 bp of the rgfA gene encoding the DNA-
binding domain, and of the first 1.055 bp of the rgfC gene in the
chromosome of L1 wild type strain (Fig. 1), as described above using
the following primers: rgfA_del1 (59-CCGCGGATCCTCAA-
CAGGCACGTTTAGAGAGA), rgfA_del2 (59-CCCATCCACTA-
AACTTAAACAAACGTCTTCAATCCTTCTGCT), rgfC_del3 (59-
TGTTTAAGTTTAGTGGATGGGGATAACGCTATTGAGGCAT-
CT), and rgfC_del4 (59-GGGGGTACCATCACTGGTGGT-
GGTTGGAT). Complementary DNA sequences in the primers
fbsB_del2and fbsB_del3 and inthe primers rgfA_del2 and rgfC_del3
are shown in italics, and the BamHI and KpnIr e s t r i c t i o n ss i t e si n
primers fbsB _del1 and fbsB_del4 and in primers rgfA _del1 and
rgfC_del4 are underlined.
Successful gene deletions in DfbsA, DfbsB, DfbsADfbsB, and
DrgfAC mutant strains were confirmed by PCR using primers
flanking the deletion site and then by sequencing the amplified
fragment.
Plasmid-mediated expression of fbsB, fbsA, and rgfAC in S.
agalactiae
The pP1 plasmid [41] was used for complementation analysis of
L1 DfbsB, DfbsA and DrgfAC isogenic mutants. The fbsA, fbsB, and
rgfAC genes, including their ribosomal binding sites, were amplified
from chromosomal DNA of L1 GBS strain by PCR using the
Herculase Hotstart DNA Polymerase(Stratagene,SantaClara,USA)
and the following primer sets: fbsB_compl1 (59-GGGGAGCT
CTATTATCTCGTGATAAGTTTTTGATG)/fbsB_compl2 (59-
CCGCGGATCCTTTAAGAT CGCCTTGATAGCAG) for fbsB
gene, fbsA_compl1 (59-GGGGAGCTCAAAAGTAAGGAG AAA-
ATTAATTGTTC)/fbsA_compl2 (59-CCGCGGATCCCCGATT-
CCTTTTTATTGATTG C) for fbsA gene, and rgf_compl1 (59-
GGGGAGCTCTCAACAGGCACGTTTAGAGAG)/rgf_compl2
(59-CCGCGGATCCATCACTGGTGGTGGTTGGATTG) for
rgfAC genes. The SacI and BamHI restriction sites used for cloning
are underlined. The fbsB, fbsA and rgfAC-containing PCR products
and the plasmid pP1 were digested with SacIa n dBamHI, ligated and
transformed into E. coli MC1061. The plasmid pP1 and the resulting
plasmids pP1-fbsB, pP1-fbsA and pP1-rgfAC were subsequently
Table 2. Oligonucleotide primers.
Name of primer Nucleotide sequence (59-39)
Amplified
fragment size
Target genes in
reference strain
GBS reference
strain
lmb130 GTTGTGAGTTTAGTAATGATAGC 840 bp lmb R268 [43]
lmb970 GATATGTCTTGTTCCGCTTG
rogB59 GCTATGATTACTACCCTTCCATTACTC 130 bp rogB 6313 [23]
rogB189 TTCGATATTCAGAGAGAGTTGACTG
rogB298 GATTCAGGCAGGTTCCCTTT 891 bp
rogB1189 CGGCTATTTGTATCGGAGGA
rogB350 GTGCAACTGCTTATCGCATAC 794 bp
rogB1144 GGTGAGCACAAAGGAGAAGAA
rogB822 TTGGTCTGAGAAGCGTATCG 131 bp
rogB953 GCAACTTTTACCAACTCGTCA
rgfB1 TCTATGGCAAAATGCTTAACG 1086 rgfBD O90R [25]
rgfD155 TCTCTAAACGTGCCTGTTGAA
rgfD89 ACGAGGAGACGAAAGTGAAT 2277 rgfDAC
rgfC CGCAAAGTTCTATGGTTCAAAA
rovS114 CAAGGTTTGAGAGAGGAGAGTCA 631 bp rovS NEM 316 [24]
rovS745 TCCTGAAGAAGTATCACCAAGTTTT
rovS82 AGCAGATGAGCACCTATCCA 146 bp
rovS228 TGAGTGTGCGCCTTAGAATG
fbsA282 CAACTTATAGGGAAAAATCCAC 123 bp fbsA 176H4A [20]
fbsA 405 AGTTAACATCGGTCTATTAGC
fbsA86 ATCAAGTCCTGTATCTGCTAT 469 bp
fbsA555rc TTCATTGCGTCTCAAACCG
fbsB354 GCGATTGTGAATAGAATGAGTG 129 bp fbsB NEM316 [18,45]
fbsB483 ACAGAAGCGGCGATTTCATT
fbsB143 TCGGTCATAAAATAGCGTATGG 1567 bp
fbsB1710rc AAGAATTCAACGGTCGGCTTCGT
gyrA CGGGACACGTACAGGCTACT 128 bp gyrA NEM316 [45]
rgyrA CGATACGAGAAGCTCCCACA
doi:10.1371/journal.pone.0014658.t002
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mutants DfbsB, DfbsA and DrgfAC.
DNA amplification
Bacterial genomic DNA (20 ng), extracted and purified by
conventional methods [42], was used as the template for PCR
assays. All primers used (Table 2) were purchased from
Eurogentec (Seraing, Belgium). The widely distributed lmb gene
[43], used as a control, was amplified with primer set lmb130/
lmb970. Four primer sets designed in various sites of the rogB gene
were used to amplify the rogB gene, and two primer sets were used
to amplify rgfBDAC locus, rovS, fbsA, and fbsB genes. The mixture
(20 mL) contained primers (0.2 mM each), deoxynucleoside
triphosphates (200 mM each), Taq DNA polymerase (0.5 U)
(Roche Diagnostics, Mannheim, Germany), and 1.5 mM MgCl2,
in 1X buffer. The PCR consisted of an initial 5 min hold at 94uC
followed by 30 cycles, each of 1 min denaturation at 94uC,
0.5 min annealing at 55uCo ra t5 0 uC, and 1 min elongation at
72uC, followed by a final 10 min elongation step at 72uC
(GeneAmpH PCR System 2700, Applied Biosystems, Foster City,
USA).
Quantification of specific transcripts with real-time PCR
S. agalactiae L1 wild type isolate and isogenic mutant strains
were grown in 50 ml of TH broth to stationary growth phase
([OD595] =1.2). Bacterial cells pelleted by centrifugation were
lysed mechanically with 0.25–0.5 mm glass beads (Sigma) in
Tissue Lyser (Qiagen, Hilden, Germany) for 6 min at 30 Hz.
RNA was purified by using the RNeasy Mini kit (Qiagen), then
treated with DNase using DNAfree kit (Ambion, Cambridgeshire,
UK) and checked for DNA contamination by PCR amplification
without prior reverse transcription. As no amplicons were
obtained, the possibility of DNA contamination during RNA
preparation could be excluded. Reverse transcription of 1 mgo f
RNA was performed with random hexanucleotides and the
Quantiscript Reverse Transcription kit (Qiagen). Real-time
quantitative PCR was performed in a 25 ml reaction volume
containing cDNA (50 ng), 12.5 ml QuantiTect SYBR Green PCR
Master Mix (Qiagen), and 0.3 mM of each gene-specific primer set
in an iCycler iQ detection system (BioRad). The specific primers
for gyrA, fbsA (fbsA282/fbsA405), fbsB (fbsB354/fbsB483) and rovS
(rovS82/rovS228) genes were used (Table 2). The PCR consisted of
an initial 15 min hold at 95uC followed by 40 cycles, each of
15 sec at 94uC, 30 sec at 58uC, and 30 sec with fluorescence
acquisition at 72uC. The specificity of the amplified product was
verified by generating a melting-curve with a final step of 50 cycles
of 10 sec at an initial temperature of 70uC, increasing 0.5uC each
cycle up to 95uC. The quantity of cDNA for the investigated genes
was normalized to the quantity of gyrA cDNA in each sample. The
gyrA gene was chosen as an internal standard since gyrase genes
represent ubiquitously expressed house-keeping genes that are
frequently used for the normalization of gene expression in
quantitative reverse transcription-PCR experiments [23,24,44].
The transcription levels of fbsB, fbsA and rovS genes in wild type
isolates were treated as the basal levels. Each experiment was
performed at least three times. Gene transcript levels of isogenic
mutant strains were expressed as fold-transcript levels relative to
those of the parental strains. A twofold difference was interpreted
as a significant difference in expression between the parental and
the mutant strains.
Binding of S. agalactiae to immobilized human
fibrinogen
All binding assays were performed in triplicate as previously
described [17]. Briefly, flat bottomed 96-well polystyrene plates
were coated for 18 h at 4uC with 21 nM human fibrinogen
(Diagnostica Stago, Asnie `res, France) diluted in phosphate-
buffered saline (PBS) (150 mM NaCl, 10 mM sodium phosphate,
pH 7.2). Bacterial cells were harvested from overnight cultures in
TH broth and resuspended in PBS. Fibrinogen-coated wells were
washed, and then 50 ml of PBS containing 5610
6 to 5610
8 CFU
per ml were added to each well. After incubation for 90 min at
37uC, non binding bacteria were removed by washing with PBS.
Bound bacteria were subsequently unbound by the addition of a
0.01% solution of protease/serine protease mix (Sigma) to each
well, then the viable bacteria were quantified by plating serial
dilutions onto TS agar plates. The percentage of binding to
human fibrinogen was obtained by the ratio between the number
of bound bacteria and the number of bacteria present in the
inoculum. Statistically significant difference in fibrinogen-binding
ability was determined at 95% confidence level (P,0.05) for a two-
sample t-test assuming unequal variance.
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